Campbell McInnes to Protein Kinase Inhibitors
This is a "connection" page, showing publications Campbell McInnes has written about Protein Kinase Inhibitors.
Connection Strength
5.693
-
A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics. J Med Chem. 2022 02 24; 65(4):3420-3433.
Score: 0.631
-
Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE. Eur J Med Chem. 2022 Jan 05; 227:113926.
Score: 0.618
-
Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation. J Med Chem. 2019 04 25; 62(8):3886-3897.
Score: 0.519
-
The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1. Cell Chem Biol. 2018 09 20; 25(9):1107-1116.e4.
Score: 0.493
-
Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy. Bioorg Med Chem Lett. 2016 08 01; 26(15):3754-60.
Score: 0.426
-
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors. J Vis Exp. 2015 Oct 26; (105):e52441.
Score: 0.408
-
Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity. J Med Chem. 2015 Jan 08; 58(1):433-42.
Score: 0.385
-
Fragment based discovery of arginine isosteres through REPLACE: towards non-ATP competitive CDK inhibitors. Bioorg Med Chem. 2014 Jan 01; 22(1):616-22.
Score: 0.356
-
Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics. Biochem Pharmacol. 2009 May 15; 77(10):1561-71.
Score: 0.255
-
Progress in the evaluation of CDK inhibitors as anti-tumor agents. Drug Discov Today. 2008 Oct; 13(19-20):875-81.
Score: 0.247
-
Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol. 2006 Nov; 2(11):608-17.
Score: 0.218
-
Improved lead-finding for kinase targets using high-throughput docking. Curr Opin Drug Discov Devel. 2006 May; 9(3):339-47.
Score: 0.211
-
PharmaDiscovery 2005. Kinases in drug discovery. IDrugs. 2005 Jul; 8(7):551-4.
Score: 0.200
-
Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer. Expert Opin Drug Discov. 2023 01; 18(1):65-81.
Score: 0.168
-
Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells. J Med Chem. 2021 07 22; 64(14):9916-9925.
Score: 0.151
-
Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chem Biol. 2010 Oct 29; 17(10):1111-21.
Score: 0.072
-
Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem. 2010 Jun 10; 53(11):4367-78.
Score: 0.070
-
Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors. J Med Chem. 2010 Mar 11; 53(5):2136-45.
Score: 0.069
-
Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design. ChemMedChem. 2009 Jul; 4(7):1120-8.
Score: 0.066
-
Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem. 2009 Jan 08; 52(1):74-86.
Score: 0.064
-
Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle. IDrugs. 2006 Apr; 9(4):273-8.
Score: 0.053
-
Protein structures in virtual screening: a case study with CDK2. J Med Chem. 2006 Jan 12; 49(1):92-104.
Score: 0.013